Professor Des Richardson holds the Chair of Cancer Cell Biology at the University of Sydney, Australia, and is a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow.

He is a multi-disciplinary pharmacologist whose career has spanned metabolism, medicinal chemistry, drug design/development/commercialisation, cancer biology, and neurobiology. He has published 430 articles, reviews, patents, chapters etc., over his career with >93% as first, senior or corresponding author (H-index: 89;  >33,800 citations over entire career; Google Scholar 2/12/19; with  >19,000 citations over the past 5 years and H-index: 63 over the past 5 years; Google Scholar 2/12/19). He is Executive Editor of BBA-General Subjects and has served on the Ed. Boards of 45 journals, including: JBC, Antioxidants Redox Signaling, Biochem. J., J. Clin. Pathology (Assoc. Ed.), Int. J. Biochem. Cell Biology – Molecules in Focus Editor (for 10 years), BBA-Mol Cell Res, Mol. Pharmacol., Pharmacol. Res., BBA-Reviews on Cancer, etc. As a major translational research achievement, he has developed the anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein-mediated drug resistance and up-regulates the potent metastasis suppressor, NDRG1. This has led to commercialisation of DpC and the development of the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC has entered multi-centre Phase I clinical trials for the treatment of advanced and resistant cancer. These anti-cancer drugs target the lysosome via the P-glycoprotein transporter.

IPHYS contact person: Petr Ježek, petr.jezek@fgu.cas.cz